Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001610717-24-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-01-04 | 2024-01-02 | ANTX | Krause Kevin Michael | Chief Strategy Off | M - OptEx | $0.42 | +2,583 | 4,497 | +135% | +$1,085 |
| DT | 2024-01-04 | 2024-01-02 | ANTX | Krause Kevin Michael | Chief Strategy Off | S - Sale+OE | $20.12 | -2,583 | 1,914 | -57% | -$52.0K |
| DT | 2024-01-04 | 2024-01-02 | ANTX | Krause Kevin Michael | Chief Strategy Off | M - OptEx | $0.00 | -2,583 | 52.3K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | M | A | 2,583 | $0.42 | 4,497 | D | — | — | (F3) Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023. (F2) Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023. |
| 2 | Common | Common Stock | 2024-01-02 | S | D | 2,583 | $20.12 | 1,914 | D | — | — | (F4) Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Stock Option (right to buy) | 2024-01-02 | M | D | 2,583 | $0.00 | 52,285 | D | $0.42 · — to 2030-01-22 | 2,583 Common Stock | (F5) The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date. |